HHS said it would terminate Women’s Health Initiative, then reconsidered

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Cancer Policy

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS and the Centers for Medicare & Medicaid Services deferred more than $1 billion in federal Medicaid payments to California and Minnesota as these states submit additional documentation supporting certain Medicaid claims.

HHS joins Trump’s drive to use AI to address chronic disease

HHS has joined President Trump’s “Genesis Mission,” an artificial intelligence platform to harness federal scientific datasets. The purpose of the move is to use AI to further Robert F. Kennedy Jr.’s efforts to end what he calls “the chronic disease crisis,” a focal point of his Make America Healthy Again strategy.

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Clinical Roundup

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

Chronic, low-grade inflammation in the body—a phenomenon known as “inflammaging” because it increases with age—has been linked to many leading causes of illness and death, including cancer, heart disease, metabolic conditions, and neurodegenerative diseases. But scientists have struggled to understand what causes inflammaging or how to reverse its effects.

July 24, 2026

Vol.52 No.29

Drugs & Targets

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

July 24, 2026

Vol.52 No.29

HHS said it would terminate Women’s Health Initiative, then reconsidered

YOU MAY BE INTERESTED IN

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS joins Trump’s drive to use AI to address chronic disease

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Renew today!

Subscriber content

Never miss an issue!

Login

HHS said it would terminate Women’s Health Initiative, then reconsidered

YOU MAY BE INTERESTED IN

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS joins Trump’s drive to use AI to address chronic disease

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Never miss an issue!

Login

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”